News Releases

March 27, 2019
Bioventus Launches OSTEOAMP SELECT Fibers
DURHAM, NC – March 27, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching OSTEO AMP SELECT Fibers , an innovative addition to its allograft line of OSTEOAMP bone graft substitutes for spine, foot & ankle, orthopaedic, and trauma surgeons.
Read More
January 29, 2019
Bioventus Launches DUROLANE in Malaysia
HOOFDDORP, THE NETHERLANDS – January 29, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching DUROLANE , its single-injection joint-fluid osteoarthritis (OA) treatment, in Malaysia and has selected Athrotech as its exclusive distribution partner for the market.
Read More
January 15, 2019
Bioventus Launches OSTEOMATRIX+® Biphasic Bone Graft
DURHAM, NC – January 15, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching OSTEOMATRIX+, its next generation biphasic bone graft for use in bone remodeling in a variety of orthopaedic and spine applications. OSTEOMATRIX+ is a moldable bone graft substitute consisting of
Read More
October 25, 2018
Susan M. Stalnecker Named to Bioventus Board of Managers
DURHAM, NC – October 25, 2018 – Bioventus , a global leader in orthobiologic solutions, today announced the appointment of Susan M. Stalnecker, former Vice President and Treasurer, E.I. du Pont de Nemours and Company, to the company’s Board of Managers, replacing Michael Minogue.
Read More
July 23, 2018
Bioventus Enters Into Definitive Agreement to Divest BMP Program
DURHAM, NC – July 23, 2018 – Bioventus , a global leader in orthobiologic solutions, has entered into a definitive agreement to divest its next generation bone morphogenetic protein (BMP) development program to a new company formed by Viscogliosi Brothers, LLC (VB) , a private equity investment
Read More
March 5, 2018
Bioventus Launches DUROLANE in the US
DURHAM, NC – March 5, 2018 – Bioventus , a global leader in orthobiologic solutions, today launched DUROLANE , its single-injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of pain associated with knee osteoarthritis (OA) .
Read More
February 26, 2018
Bioventus to Co-Develop Next Generation Bone Allograft with LifeLink
DURHAM, NC – February 26, 2018 – Bioventus , a global leader in orthobiologic solutions, has entered into an agreement with LifeLink Tissue Bank, a division of LifeLink Foundation, Inc. headquartered in Tampa, FL, to co-develop a next generation bone allograft solution for use in spine and trauma
Read More
February 12, 2018
Bioventus to Continue Distributing SUPARTZ FX Through 2028
DURHAM, NC – February 12, 2018 – Bioventus , a global leader in orthobiologic solutions, has entered into an extension of its agreement with Seikagaku Corporation to continue distributing SUPARTZ FX ™ , a five – injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of
Read More
Displaying 101 - 110 of 112